PathoQuest publishes study on proprietary NGS-based quality control test

Paris-based SHS portfolio company PathoQuest SAS is a leader in the development and delivery of next-generation sequencing (NGS) tests for biopharmaceuticals. PathoQuest recently published a study with Charles River Laboratories International Inc. showing that PathoQuest’s GMP-compliant, NGS-based test demonstrates greater ability to detect viral contamination compared to in vivo tests.

The aim of the study was to compare conventional in vivo assays used to screen cell lines for adventitious viruses with a GMP-compliant viral transcriptome NGS assay. The study was conducted as a direct comparison of standard in vivo assays and NGS-based assays of cell substrates. Charles River’s leading experts prepared the test materials and performed the in vivo tests, while PathoQuest’s team tested the material using its proprietary NGS-based quality control.

More information: link